0	21	1,25-Dihydroxyvitamin	1,25-Dihydroxyvitamin	NNP
22	24	D3	D3	NNP
25	33	receptor	receptor	NN
34	37	RNA	RNA	NNP
37	38	:	:	:
39	49	expression	expression	NN
50	52	in	in	IN
53	66	hematopoietic	hematopoietic	JJ
67	72	cells	cell	NNS
72	73	.	.	.

75	96	1,25-Dihydroxyvitamin	1,25-Dihydroxyvitamin	NNP
97	99	D3	D3	NNP
100	101	[	[	(
101	112	1,25(OH)2D3	1,25(OH)2D3	NNP
112	113	]	]	)
114	121	induces	induce	VBZ
122	137	differentiation	differentiation	NN
138	141	and	and	CC
142	150	inhibits	inhibit	VBZ
151	164	proliferation	proliferation	NN
165	167	of	of	IN
168	175	myeloid	myeloid	JJ
176	184	leukemic	leukemic	JJ
185	190	cells	cell	NNS
191	195	from	from	IN
196	203	various	various	JJ
204	209	lines	line	NNS
210	213	and	and	CC
214	222	patients	patient	NNS
222	223	;	;	:
224	229	these	these	DT
230	237	effects	effect	NNS
238	241	are	be	VBP
242	250	probably	probably	RB
251	259	mediated	mediate	VBN
260	267	through	through	IN
268	271	the	the	DT
272	283	1,25(OH)2D3	1,25(oh)2d3	NN
284	292	receptor	receptor	NN
292	293	.	.	.

294	300	Little	little	JJ
301	303	is	be	VBZ
304	309	known	know	VBN
310	312	of	of	IN
313	323	expression	expression	NN
324	326	of	of	IN
327	338	1,25(OH)2D3	1,25(oh)2d3	NN
339	347	receptor	receptor	NN
348	351	RNA	RNA	NNP
352	354	in	in	IN
355	368	hematopoietic	hematopoietic	JJ
369	374	cells	cell	NNS
374	375	.	.	.

376	378	We	we	PRP
379	387	examined	examine	VBD
388	391	the	the	DT
392	402	expression	expression	NN
403	406	and	and	CC
407	417	modulation	modulation	NN
418	420	of	of	IN
421	431	expression	expression	NN
432	434	of	of	IN
435	446	1,25(OH)2D3	1,25(oh)2d3	NN
447	455	receptor	receptor	NN
456	459	RNA	RNA	NNP
460	462	in	in	IN
463	470	various	various	JJ
471	484	proliferating	proliferate	VBG
485	488	and	and	CC
489	505	nonproliferating	nonproliferating	JJ
506	519	hematopoietic	hematopoietic	JJ
520	525	cells	cell	NNS
525	526	.	.	.

527	539	Constitutive	constitutive	JJ
540	550	expression	expression	NN
551	553	of	of	IN
554	565	1,25(OH)2D3	1,25(oh)2d3	NN
566	574	receptor	receptor	NN
575	578	RNA	RNA	NNP
579	582	was	be	VBD
583	591	detected	detect	VBN
592	594	in	in	IN
595	602	various	various	JJ
603	608	kinds	kind	NNS
609	611	of	of	IN
612	625	hematopoietic	hematopoietic	JJ
626	631	cells	cell	NNS
631	632	,	,	,
633	642	including	include	VBG
643	654	macrophages	macrophage	NNS
655	658	and	and	CC
659	668	activated	activate	VBN
669	670	T	t	NN
671	682	lymphocytes	lymphocyte	NNS
682	683	,	,	,
684	686	as	as	RB
687	691	well	well	RB
692	694	as	as	IN
695	697	in	in	IN
698	702	cell	cell	NN
703	708	lines	line	NNS
709	713	KG-1	kg-1	NN
714	715	(	(	(
715	726	myeloblasts	myeloblast	NNS
726	727	)	)	)
727	728	,	,	,
729	734	HL-60	HL-60	NNP
735	736	(	(	(
736	749	promyelocytes	promyelocyte	NNS
749	750	)	)	)
750	751	,	,	,
752	756	ML-3	ML-3	NNP
757	758	(	(	(
758	773	myelomonoblasts	myelomonoblast	NNS
773	774	)	)	)
774	775	,	,	,
776	780	U937	U937	NNP
780	781	,	,	,
782	787	THP-1	thp-1	NN
788	789	(	(	(
789	799	monoblasts	monoblast	NNS
799	800	)	)	)
800	801	,	,	,
802	806	K562	K562	NNP
807	808	(	(	(
808	821	erythroblasts	erythroblast	NNS
821	822	)	)	)
822	823	,	,	,
824	827	and	and	CC
828	833	S-LB1	s-lb1	NN
834	835	(	(	(
835	853	HTLV-1-transfected	htlv-1-transfected	JJ
854	855	T	t	NN
856	867	lymphocytes	lymphocyte	NNS
867	868	)	)	)
868	869	.	.	.

870	878	Receptor	receptor	NN
879	890	transcripts	transcript	NNS
891	895	were	be	VBD
896	899	4.6	4.6	CD
900	909	kilobases	kilobas	NNS
910	911	(	(	(
911	913	kb	kb	NN
913	914	)	)	)
914	915	,	,	,
916	919	and	and	CC
920	922	no	no	DT
923	930	variant	variant	JJ
931	936	sizes	size	NNS
937	941	were	be	VBD
942	950	observed	observe	VBN
950	951	.	.	.

952	955	All	all	DT
956	960	cell	cell	NN
961	966	lines	line	NNS
967	975	examined	examine	VBN
976	978	in	in	IN
979	983	this	this	DT
984	989	group	group	NN
990	994	also	also	RB
995	1004	expressed	express	VBD
1005	1016	1,25(OH)2D3	1,25(oh)2d3	NN
1017	1026	receptors	receptor	NNS
1026	1027	.	.	.

1028	1032	Most	most	JJS
1033	1034	B	B	NNP
1035	1045	lymphocyte	lymphocyte	NN
1046	1051	lines	line	NNS
1052	1061	expressed	express	VBD
1062	1072	negligible	negligible	JJ
1073	1079	levels	level	NNS
1080	1082	of	of	IN
1083	1094	1,25(OH)2D3	1,25(oh)2d3	NN
1095	1103	receptor	receptor	NN
1104	1107	RNA	RNA	NNP
1108	1111	and	and	CC
1112	1119	protein	protein	NN
1119	1120	;	;	:
1121	1128	however	however	RB
1128	1129	;	;	:
1130	1138	analysis	analysis	NN
1139	1141	of	of	IN
1142	1143	a	a	DT
1144	1160	lymphoid/myeloid	lymphoid/myeloid	JJ
1161	1168	somatic	somatic	JJ
1169	1175	hybrid	hybrid	NN
1176	1185	suggested	suggest	VBD
1186	1190	that	that	IN
1191	1202	suppression	suppression	NN
1203	1205	of	of	IN
1206	1216	expression	expression	NN
1217	1219	of	of	IN
1220	1231	1,25(OH)2D3	1,25(oh)2d3	NN
1232	1240	receptor	receptor	NN
1241	1244	RNA	RNA	NNP
1245	1247	in	in	IN
1248	1249	B	B	NNP
1250	1261	lymphocytes	lymphocyte	NNS
1262	1265	may	may	MD
1266	1268	be	be	VB
1269	1270	a	a	DT
1271	1279	dominant	dominant	JJ
1280	1294	characteristic	characteristic	NN
1294	1295	.	.	.

1296	1301	HL-60	HL-60	NNP
1302	1307	cells	cell	NNS
1308	1312	were	be	VBD
1313	1321	cultured	culture	VBN
1322	1326	with	with	IN
1327	1333	10(-7)	10(-7)	CD
1334	1339	mol/L	mol/l	NN
1340	1351	1,25(OH)2D3	1,25(oh)2d3	NN
1352	1355	for	for	IN
1356	1358	24	24	CD
1359	1361	to	to	TO
1362	1364	72	72	CD
1365	1370	hours	hour	NNS
1370	1371	,	,	,
1372	1375	and	and	CC
1376	1382	levels	level	NNS
1383	1385	of	of	IN
1386	1396	expression	expression	NN
1397	1399	of	of	IN
1400	1411	1,25(OH)2D3	1,25(oh)2d3	NN
1412	1420	receptor	receptor	NN
1421	1424	and	and	CC
1425	1428	its	its	PRP$
1429	1432	RNA	RNA	NNP
1433	1437	were	be	VBD
1438	1446	examined	examine	VBN
1446	1447	.	.	.

1448	1454	Levels	level	NNS
1455	1457	of	of	IN
1458	1461	RNA	RNA	NNP
1462	1468	coding	coding	NN
1469	1472	for	for	IN
1473	1476	the	the	DT
1477	1485	receptor	receptor	NN
1486	1490	were	be	VBD
1491	1494	not	not	RB
1495	1504	modulated	modulate	VBN
1505	1507	by	by	IN
1508	1516	exposure	exposure	NN
1517	1519	to	to	TO
1520	1524	high	high	JJ
1525	1531	levels	level	NNS
1532	1534	of	of	IN
1535	1541	ligand	ligand	NN
1541	1542	.	.	.

1543	1549	Levels	level	NNS
1550	1552	of	of	IN
1553	1561	occupied	occupy	VBN
1562	1573	1,25(OH)2D3	1,25(oh)2d3	NN
1574	1582	receptor	receptor	NN
1583	1590	protein	protein	NN
1591	1600	increased	increase	VBD
1601	1603	in	in	IN
1604	1609	these	these	DT
1610	1615	HL-60	hl-60	NN
1616	1621	cells	cell	NNS
1621	1622	;	;	:
1623	1626	but	but	CC
1627	1630	the	the	DT
1631	1636	total	total	JJ
1637	1643	number	number	NN
1644	1646	of	of	IN
1647	1658	1,25(OH)2D3	1,25(oh)2d3	NN
1659	1668	receptors	receptor	NNS
1669	1678	decreased	decrease	VBD
1679	1684	about	about	RB
1685	1687	50	50	CD
1687	1688	%	%	NN
1689	1691	at	at	IN
1692	1694	24	24	CD
1695	1700	hours	hour	NNS
1701	1704	and	and	CC
1705	1713	returned	return	VBD
1714	1720	toward	toward	IN
1721	1727	normal	normal	JJ
1728	1730	at	at	IN
1731	1733	72	72	CD
1734	1739	hours	hour	NNS
1739	1740	.	.	.

1741	1753	Steady-state	steady-state	JJ
1754	1760	levels	level	NNS
1761	1763	of	of	IN
1764	1775	1,25(OH)2D3	1,25(oh)2d3	NN
1776	1784	receptor	receptor	NN
1785	1788	RNA	RNA	NNP
1789	1793	were	be	VBD
1794	1797	not	not	RB
1798	1806	affected	affect	VBN
1807	1809	by	by	IN
1810	1818	terminal	terminal	JJ
1819	1834	differentiation	differentiation	NN
1835	1837	of	of	IN
1838	1843	HL-60	hl-60	NN
1844	1850	toward	toward	IN
1851	1857	either	either	CC
1858	1870	granulocytes	granulocyte	NNS
1871	1873	or	or	CC
1874	1885	macrophages	macrophage	NNS
1885	1886	.	.	.

1887	1898	Nondividing	nondivide	VBG
1899	1910	macrophages	macrophage	NNS
1911	1915	from	from	IN
1916	1922	normal	normal	JJ
1923	1934	individuals	individual	NNS
1935	1939	also	also	RB
1940	1949	expressed	express	VBD
1950	1961	1,25(OH)2D3	1,25(oh)2d3	NN
1962	1970	receptor	receptor	NN
1971	1974	RNA	RNA	NNP
1974	1975	.	.	.

1976	1978	In	in	IN
1979	1987	contrast	contrast	NN
1987	1988	,	,	,
1989	2000	nondividing	nondividing	JJ
2001	2011	peripheral	peripheral	JJ
2012	2017	blood	blood	NN
2018	2029	lymphocytes	lymphocyte	NNS
2030	2034	from	from	IN
2035	2041	normal	normal	JJ
2042	2053	individuals	individual	NNS
2054	2057	did	do	VBD
2058	2061	not	not	RB
2062	2069	express	express	VB
2070	2081	1,25(OH)2D3	1,25(oh)2d3	NN
2082	2090	receptor	receptor	NN
2091	2094	RNA	RNA	NNP
2094	2095	;	;	:
2096	2100	with	with	IN
2101	2112	stimulation	stimulation	NN
2113	2115	of	of	IN
2116	2129	proliferation	proliferation	NN
2130	2132	of	of	IN
2133	2138	these	these	DT
2139	2144	cells	cell	NNS
2144	2145	,	,	,
2146	2158	accumulation	accumulation	NN
2159	2161	of	of	IN
2162	2173	1,25(OH)2D3	1,25(oh)2d3	NN
2174	2182	receptor	receptor	NN
2183	2186	RNA	RNA	NNP
2187	2196	increased	increase	VBD
2197	2205	markedly	markedly	RB
2205	2206	.	.	.

2207	2216	Half-life	half-life	NN
2217	2218	(	(	(
2218	2222	t1/2	t1/2	NN
2222	2223	)	)	)
2224	2226	of	of	IN
2227	2238	1,25(OH)2D3	1,25(oh)2d3	NN
2239	2247	receptor	receptor	NN
2248	2251	RNA	RNA	NNP
2252	2254	in	in	IN
2255	2256	T	t	NN
2257	2268	lymphocytes	lymphocyte	NNS
2269	2272	was	be	VBD
2273	2278	short	short	JJ
2279	2280	(	(	(
2280	2281	1	1	CD
2282	2286	hour	hour	NN
2286	2287	)	)	)
2288	2290	as	as	IN
2291	2301	determined	determine	VBN
2302	2304	by	by	IN
2305	2314	measuring	measure	VBG
2315	2320	decay	decay	NN
2321	2323	of	of	IN
2324	2327	the	the	DT
2328	2335	message	message	NN
2336	2341	after	after	IN
2342	2350	addition	addition	NN
2351	2353	of	of	IN
2354	2365	actinomycin	actinomycin	NN
2366	2368	D.	D.	NNP
2369	2379	Consistent	Consistent	NNP
2380	2384	with	with	IN
2385	2389	this	this	DT
2390	2395	short	short	JJ
2396	2400	t1/2	t1/2	NN
2400	2401	,	,	,
2402	2414	accumulation	accumulation	NN
2415	2417	of	of	IN
2418	2429	1,25(OH)2D3	1,25(oh)2d3	NN
2430	2438	receptor	receptor	NN
2439	2442	RNA	RNA	NNP
2443	2452	increased	increase	VBD
2453	2455	in	in	IN
2456	2461	cells	cell	NNS
2462	2464	as	as	IN
2465	2470	their	their	PRP$
2471	2478	protein	protein	NN
2479	2488	synthesis	synthesis	NN
2489	2492	was	be	VBD
2493	2502	inhibited	inhibit	VBN
2502	2503	.	.	.

2504	2511	Further	further	JJ
2512	2519	studies	study	NNS
2520	2523	are	be	VBP
2524	2532	required	require	VBN
2533	2535	to	to	TO
2536	2546	understand	understand	VB
2547	2550	the	the	DT
2551	2562	physiologic	physiologic	JJ
2563	2567	role	role	NN
2568	2570	of	of	IN
2571	2582	1,25(OH)2D3	1,25(oh)2d3	NN
2583	2592	receptors	receptor	NNS
2593	2595	in	in	IN
2596	2603	myeloid	myeloid	JJ
2604	2609	cells	cell	NNS
2610	2613	and	and	CC
2614	2627	proliferating	proliferate	VBG
2628	2629	T	t	NN
2630	2641	lymphocytes	lymphocyte	NNS
2641	2642	.	.	.